PALL PRESENTS BLOOD TREATMENT TECHNOLOGY FINDINGS

Pall Corporation recently presented, at the FDA's request, the latest research results on the effectiveness of a device to treat blood infected with transmissible spongiform encephalopathies (TSE).

The company developed the Pall Leukotrap Affinity Prion Reduction Filter system, which is used to treat TSE, a fatal neurodegenerative disease that includes Creutzfeldt-Jakob disease, the human form of "mad cow disease." The device filters infections out of the blood for a variety of neurodegenerative diseases.

According to Samuel Coker, who has led the development of the filter, this device has been effective in treating TSE. "These results demonstrate robust performance of the Leukotrap Affinity Prion Reduction Filter in removing different strains of prions," Coker said.